Safety and Efficacy of ProQuad® in Children 6-24 Month Being Evaluated for Solid Organ Transplant

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

November 3, 2016

Study Completion Date

November 3, 2016

Conditions
RENAL INSUFFICIENCY, CHRONICLIVER FAILURE, ACUTEHEART DISEASE
Interventions
BIOLOGICAL

ProQuad

"2\) Patients 6 months to 24 months of age who are being considered and/or evaluated for any solid organ transplant within the next five (5) years who are willing:~1. to receive two doses of ProQuad® at least 30 days but no more than 365 days apart.~2. to participate in the three (3) antibody titer blood draws."

Trial Locations (1)

29425

Medical University of South Carolina, Pediatric Nephrology, Charleston

All Listed Sponsors
lead

Medical University of South Carolina

OTHER

NCT02687763 - Safety and Efficacy of ProQuad® in Children 6-24 Month Being Evaluated for Solid Organ Transplant | Biotech Hunter | Biotech Hunter